AI-614

AI-614 is a bispecific monoclonal antibody currently in development by Apeximmune for the treatment of a broad range of malignancies, including solid tumors and hematologic cancers. The therapeutic agent is engineered to simultaneously target AIM-104 and Tumor-Associated Antigen 3 (TAA3). By utilizing this dual-targeting approach, AI-614 aims to selectively engage the immune system or inhibit specific oncogenic signaling pathways within the tumor microenvironment to promote anti-tumor activity. As part of Apeximmune's pipeline of antibody-based modulators, AI-614 represents an expansion of their bispecific platform focusing on undisclosed tumor-associated antigens in combination with their proprietary AIM-104 target.